Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 2/2017

01-06-2017 | Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

The Causes and Clinical Spectrum of Drug-Induced Cholestatic Liver Injury

Authors: Lara Dakhoul, Raj Vuppalanchi

Published in: Current Hepatology Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

A variety of drugs, most notably anabolic steroids and some herbal and dietary supplements (HDS), are associated with drug-induced liver injury (DILI) and cholestasis. In the current review, we highlight the recent data on cholestatic DILI and discuss the potential for novel agents as therapeutic options.

Recent Findings

The clinical phenotype of cholestatic DILI is currently defined based on the “R” ratio calculated from the liver biochemistries at the time of initial presentation. Based on histology, cholestatic DILI may be categorized as acute cholestasis, chronic cholestasis, and cholestatic hepatitis. Histologic injuries include cholangiodestructive features and bile duct loss with the later presentation associated with prolonged recovery period and a poorer prognosis. Current management approaches include early discontinuation of the offending agent, close monitoring, symptom management, selective use of liver biopsy for prognostication, and use of hepatoprotective agents such as ursodeoxycholic acid. Novel treatment agents that are currently under evaluation for the treatment of cholestatic diseases may have a role in the treatment of cholestatic DILI.

Summary

Cholestatic DILI is increasingly being appreciated, especially in the context of HDS with anabolic steroids. Recent studies report prolonged recovery period and poor prognosis when associated with bile duct loss.
Literature
1.
• Chalasani N, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–52. e7. This is the largest series of prospective DILI cases published till date with discussion about phenotype and outcomes. CrossRefPubMedPubMedCentral
2.
Andrade RJ, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.CrossRefPubMed
3.
Chalasani N, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–34. 1934 e1-4 CrossRefPubMedPubMedCentral
4.
Avigan MI, et al. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. Drug Saf. 2014;37(Suppl 1):S19–31.CrossRefPubMed
5.
Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007;11(3):477–505. v CrossRefPubMed
6.
7.
Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–44.CrossRefPubMed
8.
Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol. 2007;102(3):558–62. quiz 693 CrossRefPubMed
9.
10.
Au JS, Navarro VJ, Rossi S. Review article: drug-induced liver injury—its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther. 2011;34(1):11–20.CrossRefPubMed
11.
Sgro C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5.CrossRefPubMed
12.
Bjornsson ES, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25. 1425 e1-3; quiz e19-20 CrossRefPubMed
13.
Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med. 1992;232(2):133–8.CrossRefPubMed
14.
Suzuki A, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33(6):503–22.CrossRefPubMed
15.
Lucena MI, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55(4):820–7.CrossRefPubMed
16.
Rockey DC, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117–26.CrossRefPubMedPubMedCentral
17.
Lusetti M, et al. Pathological changes in anabolic androgenic steroid users. J Forensic Legal Med. 2015;33:101–4.CrossRef
18.
Kleiner DE. The histopathological evaluation of drug-induced liver injury. Histopathology. 2017;70(1):81–93.CrossRefPubMed
19.
Bonkovsky HL, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65(4):1267–77.
20.
Kleiner DE, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59(2):661–70.CrossRefPubMed
21.
Fontana RJ, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110(10):1450–9.CrossRefPubMedPubMedCentral
22.
23.
Tandon P, et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007;102(7):1528–36.CrossRefPubMed
24.
Xie W, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A. 2001;98(6):3375–80.CrossRefPubMedPubMedCentral
25.
Fountain FF, et al. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection. Am J Med Sci. 2009;337(5):317–20.CrossRefPubMed
26.
Dossing M, et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996;77(4):335–40.CrossRefPubMed
27.
Durand F, et al. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf. 1996;15(6):394–405.CrossRefPubMed
28.
El-Sherbiny GA, Taye A, Abdel-Raheem IT. Role of ursodeoxycholic acid in prevention of hepatotoxicity caused by amoxicillin-clavulanic acid in rats. Ann Hepatol. 2009;8(2):134–40.PubMed
29.
Song P, Zhang Y, Klaassen CD. Dose-response of five bile acids on serum and liver bile acid concentrations and hepatotoxicty in mice. Toxicol Sci. 2011;123(2):359–67.CrossRefPubMedPubMedCentral
30.
Stine JG, Chalasani N. Chronic liver injury induced by drugs: a systematic review. Liver Int. 2015;35(11):2343–53.CrossRefPubMed
31.
Regev A, Bjornsson ES. Drug-induced liver injury: morbidity, mortality, and Hy’s law. Gastroenterology. 2014;147(1):20–4.CrossRefPubMed
32.
Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241–3.CrossRefPubMed
33.
34.
Bonkovsky HL, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65(4):1267–77.CrossRefPubMed
35.
Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–9.
36.
De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8):1187–95.
37.
Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998;339(17):1217–27.CrossRefPubMed
38.
Nicoletti P, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017;152(5):1078–89.
39.
Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3(1):5.PubMedPubMedCentral
40.
Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab Rev. 2010;42(3):437–45.CrossRefPubMed
41.
Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology. 2010;52(2):748–61.CrossRefPubMed
42.
Chen R, et al. Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort. Tuberculosis (Edinb). 2015;95(1):68–74.CrossRef
43.
Lang C, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007;17(1):47–60.CrossRefPubMed
44.
Urban TJ, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012;22(11):784–95.CrossRefPubMedPubMedCentral
45.
Plummer JL, Cousins MJ, Hall P. Hypoxia and halothane hepatotoxicity. Anesth Analg. 1983;62(9):859–61.
46.
Vuppalanchi R, et al. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin Gastroenterol Hepatol. 2014;12(9):1550–5.CrossRefPubMed
47.
48.
Anwer MS, Stieger B. Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch. 2014;466(1):77–89.CrossRefPubMed
49.
Meier PJ, Stieger B. Molecular mechanisms in bile formation. News Physiol Sci. 2000;15:89–93.PubMed
50.
Beuers U, et al. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(1 Suppl):S25–37.CrossRefPubMed
51.
Baghdasaryan A, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol. 2016;64(3):674–81.
52.
Ballet F. FXR: big fish or small fry for drug-induced liver injury? Clin Res Hepatol Gastroenterol. 2016;40(1):6–8.CrossRefPubMed
53.
Metadata
Title
The Causes and Clinical Spectrum of Drug-Induced Cholestatic Liver Injury
Authors
Lara Dakhoul
Raj Vuppalanchi
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 2/2017
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0347-9

Other articles of this Issue 2/2017

Current Hepatology Reports 2/2017 Go to the issue

Management of the Cirrhotic Patient (A Cardenas and N Reau, Section Editors)

Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?

Management of the Cirrhotic Patient (A Cardenas and N Reau, Section Editors)

Biomarkers and Liver Disease: Can We Predict Decompensation with suPAR?

Hepatitis B (J Lim, Section Editor)

Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection

Management of the Cirrhotic Patient (A Cardenas and N Reau, Section Editors)

Portal Vein Thrombosis and Cirrhosis: The Role of Anticoagulation

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Multidisciplinary Team Management of Patients with Hepatocellular Carcinoma

Hepatitis B (J Lim, Section Editor)

Management of Chronic Hepatitis B in Children
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits